AJCN Tufts Nutrition Symposium, Boston & Online Sept 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Das, U. N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Das, U. N
Agricola
Right arrow Articles by Das, U. N
American Journal of Clinical Nutrition, Vol. 85, No. 6, 1665-1666, June 2007
© 2007 American Society for Nutrition


LETTER TO THE EDITOR

Is depression a low-grade systemic inflammatory condition?

Undurti N Das

UND Life Sciences
13800 Fairhill Road, no. 321
Shaker Heights, OH 44120
E-mail: undurti{at}hotmail.com

Dear Sir:

The conclusion of the recent meta-analysis by Appleton et al (1) that depression is more likely in those whose intakes of long-chain polyunsaturated fatty acids (LCPUFAs), especially of n–3 fatty acids, are low suggests that depression could be a disorder of low-grade systemic inflammatory condition because LCPUFAs modulate proinflammatory events.

Recent studies showed that proinflammatory cytokines might cause depressive illness. This conclusion is based on the observations that 1) activation of the immune system and administration of endotoxin (lipopolysaccharide; LPS) or interleukin-1 (IL-1) to experimental animals induces sickness behavior that resembles depression (2); 2) activation of the immune system is observed in many depressed patients (3); 3) depression is more frequent in those with medical disorders associated with immune dysfunction (4); 4) treatment of patients with cytokines can produce symptoms of depression (4); 5) chronic treatment with antidepressants inhibits sickness behavior induced by LPS (5); 6) pro-inflammatory cytokines activate the hypothalamo-pituitary-adrenocortical axis (HPAA), which is activated in depressed patients (2); 7) cytokines activate cerebral noradrenergic systems, which is known to occur in depressed patients (4); and 8) several proinflammatory cytokines activate brain serotonergic systems, which have been implicated in major depressive illness and its treatment (6, 7). These results suggest that depression could be a low-grade systemic inflammatory condition.

The central nervous system regulates the production of the proinflammatory cytokines: tumor necrosis factor, IL-1, high mobility group-1, IL-6, and macrophage migration inhibitory factor through the efferent vagus nerve (8, 9). Acetylcholine, the principal vagal neurotransmitter, inhibits the production of proinflammatory cytokines through a mechanism dependent on the {alpha}7 nicotinic acetylcholine receptor subunit. Because vagal nerve stimulation (VNS) is of benefit in depression, I proposed that the beneficial effect of VNS in depression is due to its inhibitory action on the production of proinflammatory cytokines (10).

A significant decrease in n–3 fatty acids in plasma or in the membranes of red blood cells has been reported in subjects with depression (1113). n–3 Fatty acids suppress the production of IL-1ß, IL-2, IL-6, and TNF-{alpha}; therefore, n–3 fatty acids could play a major role in depression through their role in maintaining membrane fluidity, which influences neurotransmission, and in modulating the production of proinflammatory cytokines (14). In addition, antidepressants exhibit an immunoregulating effect by reducing the release of proinflammatory cytokines, by increasing the release of endogenous antagonists of proinflammatory cytokines such as IL-10 and, finally, by acting like inhibitors of cyclooxygenase (15). Double-blind placebo-controlled and other studies have shown that consumption of the n–3 fatty acids eicosapentaenoic acid and docosahexaenoic acid is associated with a longer period of remission in depressed patients (1618). Thus, epidemiologic, experimental, and clinical data favor the idea that polyunsaturated fatty acids could play a role in the pathogenesis and treatment of depression. Well-planned larger trials with adequate power to detect clinically important benefits are required to determine the relevant dose of fatty acids to be used for the treatment of depression.

ACKNOWLEDGMENTS

The author had no conflict of interest to declare.

REFERENCES

  1. Appleton KM, Hayward RC, Gunnell D, et al. Effects of n–3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006;84:1308–16.[Abstract/Free Full Text]
  2. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201–17.[Medline]
  3. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004;19:397–403.[Medline]
  4. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005;29:891–909.[Medline]
  5. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002;16:569–74.[Medline]
  6. Sluzewska A, Rybakowski J, Bosmans E, et al. Indicators of immune activation in major depression. Psychiatry Res 1996;64:161–7.[Medline]
  7. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005;20:473–6.[Medline]
  8. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458–62.[Medline]
  9. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 2005;4:673–83.[Medline]
  10. Das UN. Vagus nerve stimulation, depression and inflammation. Pscychoneuropharmacol (in press).
  11. Colin A, Reggers J, Castronovo V, Anssean M. Lipids, depression, and suicide. Encephale 2003;29:49–58.[Medline]
  12. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder: a preliminary double-blind, placebo-controlled trial. Eur Neuropscychopharmacol 2003;13:267–71.
  13. Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenia and bipolar mood disorder patients. Psychiatry Res 2003;121:109–22.[Medline]
  14. Kumar SG, Das UN. Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. Prostaglandins Leukot Essent Fatty Acids 1994;50:331–4.[Medline]
  15. Denkins Y, Kempf D, Ferniz M, Nileshwar S, Marchetti D. Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. J Lipid Res 2005;46:1278–84.[Abstract/Free Full Text]
  16. Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006;163:969–78.[Abstract/Free Full Text]
  17. De Vriese SR, Christophe AB, Maes M. In humans, the seasonal variation in poly-unsaturated fatty acids is related to the seasonal variation in violent suicide and serotonergic markers of violent suicide. Prostaglandins Leukot Essent Fatty Acids 2004;71:13–8.[Medline]
  18. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003;62:195–204.[Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Das, U. N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Das, U. N
Agricola
Right arrow Articles by Das, U. N


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS